Citation: American Journal of Cardiology. 111(7):973-8, 2013 Apr 1..Journal: The American journal of cardiology.Published: 2013ISSN: 0002-9149.Full author list: Badr S; Barbash IM; Chen F; Dvir D; Kent KM; Kitabata H; Loh JP; Minha S; Pendyala LK; Pichard AD; Sardi GL; Satler LF; Suddath WO; Torguson R; Waksman R.UI/PMID: 23337837.Subject(s): *Coronary Artery Disease/dt [Drug Therapy] | *Drug-Eluting Stents | *Immunosuppressive Agents/ad [Administration & Dosage] | *Sirolimus/aa [Analogs & Derivatives] | *Sirolimus/ad [Administration & Dosage] | Coronary Angiography | Coronary Artery Disease/mo [Mortality] | Endpoint Determination | Female | Humans | Incidence | Male | Middle Aged | Proportional Hazards Models | Registries | Retrospective Studies | Survival Rate | Treatment Outcome | Ultrasonography, InterventionalInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Comparative Study | Journal ArticleOnline resources: Click here to access onlineDigital Object Identifier: (Click here)Abbreviated citation: Am J Cardiol. 111(7):973-8, 2013 Apr 1.Local Holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006.Abstract: Although second-generation everolimus-eluting stents (EESs) have demonstrated superiority over first-generation paclitaxel-eluting stents for a broad subset of patients and lesions, it is unclear whether the same applies to sirolimus-eluting stents (SESs). The present study compared the long-term clinical outcomes between EESs and SESs in patients with small coronary artery disease. A cohort of 643 patients treated with EESs (220 patients with 245 lesions) or SESs (423 patients with 523 lesions) in small vessel lesions (defined as those receiving stents <=2.5 mm) were retrospectively analyzed. The end points included target lesion revascularization, target vessel revascularization, major adverse cardiovascular events (all-cause death, myocardial infarction, or target lesion revascularization), and definite stent thrombosis at 1 year of follow-up. The baseline characteristics were generally similar between the 2 groups, except that more systemic hypertension was seen in the EES group and more patients had a family history of coronary artery disease in the SES group. The 1-year target lesion revascularization (5.6% vs 4.8%, p = 0.68) and target vessel revascularization (5.6% vs 7.6%, p = 0.33) rates showed no significant differences between the EES and SES groups. Overall major adverse cardiovascular events occurred in 9.1% of the EES- and 8.6% of SES-treated patients (p = 0.83). This similar major adverse cardiovascular events rate remained after adjustment. The rate of stent thrombosis was 0% in the EES group and 1.2% in the SES group (p = 0.17). In conclusion, EESs demonstrated comparable clinical outcomes to those of SESs in small vessel interventions. The absence of stent thrombosis among patients treated with EESs suggests a good safety profile for this second-generation drug-eluting stent, which should be carefully studied in a larger series of patients with small vessel disease. Copyright 2013 Elsevier Inc. All rights reserved.